Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorinostat with Capecitabine and Cisplatin in Gastric Cancer
NCT01045538Phase 2Completed
- Sponsor
- Asan Medical Center
- Start
- Feb 2010
- Primary completion
- Feb 2016
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vorinostat in gastric cancer (GC), sponsored by Asan Medical Center. Primary endpoints: Maximum Tolerated Dose at 3 weeks and Objective Response Rate at 6 months. Started Feb 2010; status: completed.
02
Drugs
vorinostat
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT01045538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01045538.